Related Experiment Video
Updated: Mar 17, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.1K
TRAIL gene expression analysis in multiple sclerosis patients.
Mohammad Taheri1, Shirin Nemati1, Abolfazl Movafagh1
1Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Human Antibodies
|July 30, 2016
Summary
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene expression did not differ between multiple sclerosis patients and healthy controls. TRAIL levels showed no correlation with disease characteristics in this interferon-beta treated cohort.
Area of Science:
- Neuroimmunology
- Molecular Biology
Background:
- Multiple sclerosis (MS) is an autoimmune disease targeting the central nervous system's myelin sheath.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) modulates T cell responses.
Purpose of the Study:
- To compare TRAIL gene expression in peripheral blood of MS patients and healthy controls.
- To investigate the correlation between TRAIL expression and MS clinical characteristics.
Main Methods:
- Case-control study involving 50 MS patients and 50 matched healthy controls.
- TaqMan Real-time PCR used to quantify TRAIL mRNA expression.
- Analysis of TRAIL expression correlation with age of onset, disease duration, and EDSS.
Main Results:
- No statistically significant difference in TRAIL mRNA expression between MS patients and controls (p > 0.05).
- No correlation found between TRAIL expression and clinical parameters (age of onset, disease duration, EDSS).
- Interferon-beta treatment in responders may influence TRAIL expression, masking potential differences.
Conclusions:
- TRAIL gene expression is not significantly altered in this cohort of interferon-beta treated MS patients.
- Further studies comparing responders and non-responders are recommended to elucidate TRAIL's role.
